# STOCKHOLM 1.0
#=GF ID   CoV_Methyltr_2
#=GF AC   PF06460.16
#=GF DE   Coronavirus 2'-O-methyltransferase
#=GF PI   NSP13; NSP16;
#=GF AU   Yeats C;0000-0003-0080-6242
#=GF AU   El-Gebali S;0000-0003-1378-5495
#=GF SE   ADDA_12678
#=GF GA   27.00 27.00;
#=GF TC   44.70 42.20;
#=GF NC   26.80 25.40;
#=GF BM   hmmbuild HMM.ann SEED.ann
#=GF SM   hmmsearch -E 1000 --cpu 4 -Z 75585367 HMM pfamseq
#=GF TP   Domain
#=GF CL   CL0063
#=GF RN   [1]
#=GF RM   21637813
#=GF RT   Crystal structure and functional analysis of the
#=GF RT   SARS-coronavirus RNA cap 2'-O-methyltransferase nsp10/nsp16
#=GF RT   complex.
#=GF RA   Decroly E, Debarnot C, Ferron F, Bouvet M, Coutard B, Imbert I,
#=GF RA   Gluais L, Papageorgiou N, Sharff A, Bricogne G, Ortiz-Lombardia
#=GF RA   M, Lescar J, Canard B;
#=GF RL   PLoS Pathog. 2011;7:e1002059.
#=GF RN   [2]
#=GF RM   22022266
#=GF RT   Biochemical and structural insights into the mechanisms of SARS
#=GF RT   coronavirus RNA ribose 2'-O-methylation by nsp16/nsp10 protein
#=GF RT   complex.
#=GF RA   Chen Y, Su C, Ke M, Jin X, Xu L, Zhang Z, Wu A, Sun Y, Yang Z,
#=GF RA   Tien P, Ahola T, Liang Y, Liu X, Guo D;
#=GF RL   PLoS Pathog. 2011;7:e1002294.
#=GF RN   [3]
#=GF RM   18417574
#=GF RT   Coronavirus nonstructural protein 16 is a cap-0 binding enzyme
#=GF RT   possessing (nucleoside-2'O)-methyltransferase activity.
#=GF RA   Decroly E, Imbert I, Coutard B, Bouvet M, Selisko B, Alvarez K,
#=GF RA   Gorbalenya AE, Snijder EJ, Canard B;
#=GF RL   J Virol. 2008;82:8071-8084.
#=GF RN   [4]
#=GF RM   33794150
#=GF RT   SARS-CoV-2 Nsp16 activation mechanism and a cryptic pocket with
#=GF RT   pan-coronavirus antiviral potential.
#=GF RA   Vithani N, Ward MD, Zimmerman MI, Novak B, Borowsky JH, Singh S,
#=GF RA   Bowman GR;
#=GF RL   Biophys J. 2021;120:2880-2889.
#=GF RN   [5]
#=GF RM   32994211
#=GF RT   High-resolution structures of the SARS-CoV-2
#=GF RT   2'-O-methyltransferase reveal strategies for structure-based
#=GF RT   inhibitor design.
#=GF RA   Rosas-Lemus M, Minasov G, Shuvalova L, Inniss NL, Kiryukhina O,
#=GF RA   Brunzelle J, Satchell KJF;
#=GF RL   Sci Signal. 2020; [Epub ahead of print]
#=GF DR   INTERPRO; IPR009461;
#=GF DR   SO; 0000417; polypeptide_domain;
#=GF CC   This domain covers the NSP16 region of the coronavirus
#=GF CC   polyprotein. The SARS-CoV RNA cap SAM-dependent
#=GF CC   (nucleoside-2'-O-)-methyltransferase (2'-O-MTase) is a
#=GF CC   heterodimer comprising SARS-CoV nsp10 and nsp16. When bound to
#=GF CC   nsp10, nsp16 is active as a type-0 RNA cap-dependent 2'-O-MTase,
#=GF CC   ie., active only when the cap guanine is methylated at its N7
#=GF CC   position. Nsp10 binds to nsp16 through an activation surface
#=GF CC   area in nsp10, and the resulting complex exhibits RNA cap
#=GF CC   (nucleoside-2'-O)-methyltransferase activity. Nsp10 is a double
#=GF CC   zinc finger protein together with nsp4, nsp5, nsp12, nsp14, and
#=GF CC   nsp16, nsp10 has been found to be essential in the assembly of a
#=GF CC   functional replication/transcription complex. NSP16 plays a key
#=GF CC   role in viral replication as it is involved in immune response
#=GF CC   evasion through the 2'-O-methylation of coronavirus RNA, which
#=GF CC   is essential for preventing recognition by the host. It mimics
#=GF CC   the human protein CMTr1 and, unlike CMTr1, it requires NSP10 as
#=GF CC   a binding partner to activate its enzymatic activity [4]. Nsp16
#=GF CC   adopts a typical fold of the S-adenosylmethionine-dependent
#=GF CC   methyltransferase (SAM) family as defined initially for the
#=GF CC   catechol O-MTase but it lacks several elements of the canonical
#=GF CC   MTase fold, such as helices B and C. The nsp16 topology matches
#=GF CC   those of dengue virus NS5 N-terminal domain and of vaccinia
#=GF CC   virus VP39 MTases [1,2, 3]. Structural analysis in NSP16 from
#=GF CC   SARS-CoV-2 identified a cryptic pocket (also present in other
#=GF CC   coronavirus such as SARS-CoV-1 and MERS) not present in human
#=GF CC   CMTr1, and the fact that NSP16 is one of the most conserved
#=GF CC   proteins of SARS-CoV-2 and related viruses, make it an
#=GF CC   interesting target for developing new antiviral treatment  for
#=GF CC   COVID-19 and other diseases caused by coronaviruses [5].
#=GF SQ   5
#=GS R1AB_SARS/6777-7073   AC P0C6X7.1
#=GS R1AB_CVMA5/6879-7175  AC P0C6X9.1
#=GS R1AB_IBVB/6328-6628   AC P0C6Y1.1
#=GS R1AB_CVH22/6459-6758  AC P0C6X1.1
#=GS R1AB_FIPV/6411-6708   AC Q98VG9.2
R1AB_SARS/6777-7073              SQAWQPGVAMPNLYKMQRMLLEKCDLQNYGENAVIPKGIMMNVAKYTQLCQYLNTLTLAVPYNMRVIHFGAGSDKGVAPGTAVLRQWLPTGTLLVDSDLNDFVSDADSTLIGDCATVHTANKWDLIISDMY....DPRTKHVTKENDSKEGFFTYLCGFIKQKLALGGSIAVKITEHSWNADLYKLMGHFSWWTAFVTNVNASSSEAFLIGANYLGK..PKEQIDGYTMHANYIFWRNTNPIQLSSYSLFDMSKFPLKLRGTAVMSLKENQINDMIYSLLEKGRLIIRENNRVVVSSDILVN.N
#=GR R1AB_SARS/6777-7073   sAS   ............................................*...................................................................................*...........................................*................................*..................................................................................................
R1AB_CVMA5/6879-7175             AADWKPGYVMPVLYKYLESPLERVNLWNYGKPITLPTGCMMNVAKYTQLCQYLSTTTLAVPANMRVLHLGAGSDKGVAPGSAVLRQWLPAGSILVDNDVNPFVSDSVASYYGNCITLPFDCQWDLIISDMY....DPLTKNIGEYNVSKDGFFTYLCHLIRDKLALGGSVAIKITEFSWNAELYSLMGKFAFWTIFCTNVNASSSEGFLIGINWLNK..TRTEIDGKTMHANYLFWRNSTMWNGGAYSLFDMSKFPLKAAGTAVVSLKPDQINDLVLSLIEKGKLLVRDTRKEVFVGDSLVN.V
#=GR R1AB_CVMA5/6879-7175  sAS   ............................................*...................................................................................*...........................................*................................*..................................................................................................
R1AB_IBVB/6328-6628              .SAWTCGYNMPELYKVQNCVMEPCNIPNYGVGITLPSGILMNVAKYTQLCQYLSKTTICVPHNMRVMHFGAGSDKGVAPGSTVLKQWLPEGTLLVDNDIVDYVSDAHVSVLSDCNKYNTEHKFDLVISDMYTDNDSKRKHEGVIANNGNDDVFIYLSSFLRNNLALGGSFAVKVTETSWHEVLYDIAQDCAWWTMFCTAVNASSSEAFLIGVNYLGA.SEKVKVSGKTLHANYIFWRNCNYLQTSAYSIFDVAKFDLRLKATPVVNLKTEQKTDLVFNLIKCGKLLVRDVGNTSFTSDSFVCT.
#=GR R1AB_IBVB/6328-6628   sAS   ............................................*...................................................................................*...........................................*................................*..................................................................................................
R1AB_CVH22/6459-6758             SAEWKCGYSMPGIYKTQRMCLEPCNLYNYGAGLKLPSGIMFNVVKYTQLCQYFNSTTLCVPHNMRVLHLGAGSDYGVAPGTAVLKRWLPHDAIVVDNDVVDYVSDADFSVTGDCATVYLEDKFDLLISDMY....DGRTKAIDGENVSKEGFFTYINGFICEKLAIGGSIAIKVTEYSWNKKLYELVQRFSFWTMFCTSVNTSSSEAFVVGINYLGDFAQGPFIDGNIIHANYVFWRNSTVMSLSYNSVLDLSKFNCKHKATVVVQLKDSDINEMVLSLVRSGKLLVRGNGKCLSFSNHLVSTK
#=GR R1AB_CVH22/6459-6758  sAS   ............................................*...................................................................................*...........................................*................................*..................................................................................................
R1AB_FIPV/6411-6708              .AEWNPGYSMPTLYKIQRMCLERCNLYNYGAQVRLPDGITTNVVKYTQLCQYLNTTTVCVPHKMRVLHLGAAGASGVAPGSTVLRRWLPDDAILVDNDLRDYVSDADFSVTGDCTSLYIEDKFDLLISDLY....DGSTKSIDGENTSKDGFFTYINGFIKEKLSLGGSAAIKITEFSWNKDLYELIQRFEYWTVFCTSVNTSSSEGFLIGINYLGPYCDKAIVDGNIMHANYIFWRNSTIMALSHNSVLDTPKFKCRCNNALIVNLKEKELNEMVVGLLRKGKLLIRNNGKLLNFGNHLVNV.
#=GR R1AB_FIPV/6411-6708   sAS   ............................................*...................................................................................*...........................................*................................*..................................................................................................
#=GC seq_cons                    uA-WpPGYuMPsLYKhQRMsLE+CNLaNYGsslsLPoGIMMNVAKYTQLCQYLNTTTLCVPHNMRVLHLGAGSDKGVAPGSAVLRQWLPcGoILVDNDlsDYVSDADsSVhGDCsTlahEcKFDLlISDMY....DsRTKsIstENsSKDGFFTYLsGFI+-KLALGGSlAIKITEaSWNc-LY-LhQ+FuaWThFCTuVNASSSEAFLIGINYLGc.ssKspIDGpTMHANYIFWRNSThhsLSuYSlFDhSKFsLKt+uTsVVsLK-cQINDMVlSLl+KGKLLVR-NGKslssSDpLVNs.
